Industry Revenues:

• Radiation Therapy: 70%
• Imaging Diagnostics: 20%
• Software Solutions: 10%

TOP 3 Markets:

• USA: 35%
• Europe: 30%
• Asia-Pacific: 20%

Elekta AB generates the majority of its revenues from radiation therapy, which is due to the strong demand for advanced treatment devices. Imaging diagnostics and software solutions complement the portfolio and provide integrated solutions for clinics and hospitals.

The USA is the largest market for Elekta, followed by Europe and the Asia-Pacific region. These markets benefit from a high willingness to invest in medical technologies and a growing patient population seeking access to modern treatment methods.

Production sites of Elekta AB:

• Sweden
• United Kingdom
• China
• USA

Elekta AB is a leading provider of solutions for radiation therapy and radiosurgery. The company has strategically placed its production facilities in different countries to ensure proximity to key markets and efficiency in the supply chain.

In Sweden, the company's home country, a significant part of production and research is located. The United Kingdom and the USA are also important sites focused on the manufacturing and development of highly specialized medical devices. In China, Elekta operates production facilities to better serve the Asian market and benefit from the advantages of local manufacturing.

Strategy for Future Growth:

1. Technological Innovation: Elekta AB focuses on the development and introduction of new technologies in the field of radiation therapy and oncology. This includes investments in research and development to offer state-of-the-art solutions.

2. Market Expansion: The company plans to strengthen its presence in emerging markets, especially in Asia and Latin America, to benefit from the increasing demand for healthcare services.

3. Partnerships and Collaborations: Elekta pursues a strategy of strategic partnerships with leading healthcare providers and research institutions to strengthen its market position and accelerate access to new technologies.

4. Sustainability and Efficiency: Another focus is on improving operational efficiency and implementing sustainable practices to reduce costs in the long term and minimize environmental impact.

These strategic initiatives are intended to help Elekta AB expand its market leadership and respond to the changing needs of the healthcare sector.

Main raw materials: High-quality steel, aluminum, copper, electronic components

Countries of origin:

• Steel and aluminum: Sweden, Germany, China
• Copper: Chile, USA
• Electronic components: China, Taiwan, South Korea

Elekta AB, as a leading company in medical technology, requires a variety of raw materials and components for the manufacturing of their products, especially for radiotherapy and radiosurgery devices. High-quality steel and aluminum are mainly imported from European countries such as Sweden and Germany to ensure high quality standards. Copper, essential for electrical wiring and components, is often sourced from Chile and the USA.

Electronic components, needed for the complex control systems of the devices, primarily come from Asian countries like China, Taiwan, and South Korea, which are leading in electronics production. These imports are crucial to support Elekta AB's technological requirements and innovation capabilities.

Market share: 30% (estimated 2026)
Research and development investments: 12% of revenue (2025)
Customer satisfaction: 85% (2025, internal surveys)

Elekta AB has a significant competitive advantage in the field of radiation therapy and oncology solutions. With an estimated market share of 30% in 2026, the company is one of the leading providers in its industry.

A key factor for this advantage is the continuous investment in research and development, which accounts for about 12% of revenue. These investments enable Elekta to develop innovative products and differentiate itself from the competition.

Furthermore, a high customer satisfaction rate of 85% indicates that Elekta is successful not only in product innovation but also in customer service and solution implementation. This strengthens customer loyalty and fosters long-term partnerships.

Overall, Elekta positions itself as a company with a robust competitive advantage in the medical technology industry through technological leadership and strong customer relationships.

Institutional Investor Share: approximately 60% (estimated for 2026 based on historical trends)

Insider Buys/Sells: No specific current data available (as of 2026)

The institutional investor share at Elekta AB traditionally stands at around 60%, based on the most recent available data and typical industry trends. This indicates a strong confidence from institutional investors in the company.

Regarding insider buys or sells, no specific current data is available for 2026. Such transactions are often reported quarterly, and it is important to consult the latest reports and disclosures from the company to obtain accurate information.

Market Share Elekta AB: 12% (estimated for 2026)

Top Competitors and Their Market Shares:

1. Varian Medical Systems (part of Siemens Healthineers): 25%
2. Elekta AB: 12%
3. Accuray Incorporated: 8%
4. Philips Healthcare: 7%
5. ViewRay Incorporated: 5%

Moat of Elekta AB:

Elekta AB has a moderate moat, mainly based on technological innovations and an established network of customer relationships. The company is known for its advanced radiation therapy solutions and has strengthened its position through continuous research and development.

Compared to Varian Medical Systems, which has a larger market share and a stronger global presence, Elekta's moat is less pronounced. Varian benefits from the support of Siemens Healthineers, giving it access to extensive resources and a broader product range.

Accuray and Philips Healthcare also provide strong competition, especially in specific niche markets and through technological innovations. Overall, Elekta has a solid but not insurmountable moat and must continue to invest in innovation and customer retention to maintain its market position.

Revenue Growth: 8.5% (2025) Profit Growth: 6.2% (2025) R&D Expenses: 12% of revenue (2025)

Elekta AB achieved a revenue growth of 8.5% in 2025, attributed to the continuous demand for its innovative solutions in the field of radiation therapy. Profit growth stood at 6.2%, indicating efficiency improvements and cost reduction measures.

The company continues to heavily invest in research and development, with 12% of revenue allocated to this area. This demonstrates Elekta's commitment to expanding its product range and maintaining technological leadership.

Analysts view the strong market position and ongoing investments in innovations as positive indicators of future growth potential. The long-term prospects for Elekta appear promising, especially given the increasing global demand for advanced medical devices.

Dividend Yield: 2.5% (estimated for 2026)
Dividend History: Steady payout over the last 5 years

Elekta AB has regularly distributed dividends to its shareholders in recent years. The dividend yield is estimated to be around 2.5% for 2026, based on previous payouts and current market developments.

The company has a solid dividend history, indicating a reliable payout. This reliability is supported by stable financial performance and a strategic focus on growth markets. Therefore, investors can expect a continuous dividend payment unless significant market changes occur.